South Korean based Celltrion, received approval for its biosimilar Infliximab in Japan and Turkey in July. The product was developed in collaboration with Hospira, and has been approved in Europe (2013) as well as in South Korea and Columbia.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
